Balch SM, Vaz-Luis I, Li T, Tayob N, et al. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast ca Breast Cancer Res Treat 2021 Jul 24. pii: 10.1007/s10549-021-06329.
PMID: 34302589